Clinical Trial Update: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination chemotherapy with pralatrexate as first-line therapy for non-Hodgkin lymphomas, including various T-cell lymphoma subtypes;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Combination chemotherapy
• Pralatrexate (pralatrexate)

Snippet

Sponsor: University of Nebraska | Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-06-25